Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets
Natural gums and mucilage are biocompatible, cheap, readily available, and represent a potential source of excipients. The authors examine the functionality of mucilage extracted from the leaves of Hibiscus rosa-sinensis Linn as an excipient in a sustained-release tablet formulation.


Pharmaceutical Technology
Volume 32, Issue 1



Radial and axial swelling of the tablet. The initial diameter and thickness of the tablet were measured, and the tablet was kept in dissolution media. The increase in diameter and thickness was measured at various time intervals. To evaluate the relation, the equilibrium degree of swelling (Q) was calculated from the radial and axial swelling ratio using the following equation:

in which Vtand Vo are volumes; Rt and Ro are radius at time t and zero, respectively; and It and Io are thickness at time t and zero, respectively (36).

Stability study. To study the effect of storage on an in vitro drug release, the stability study of the best formulation (HL6) was carried out at 40 °C and 75% relative humidity in a humidity oven. Samples were withdrawn after a three-month interval, and in vitro drug release was performed.

Results and discussion


Table I: Rheological data of dried-powdered mucilage and sodium carboxymethylcellulose (CMC).
Various physiochemical characteristics of the extracted mucilage from Hibiscus rosa-sinensis Linn were investigated. The percentage yield was 15%, and the average particle size was 180 μm. The mass loss on drying indicated the amount of moisture present in the material that was available to interact with other material. For dried mucilage, the mass loss on drying was 10.61%. The swelling ratio of mucilage was 9 in distilled water, 10 in simulated gastric fluid (0.1 N HCl), and 9 in phosphate buffer (pH 6.8). The authors concluded that the swelling of mucilage is pH-independent, and the mucilage is nonionic.


Table II: Flow properties of dried-powdered mucilage and other gums.
The viscosity of the extracted dried mucilage was compared with that of semisynthetic polymer sodium carboxymethyl cellulose (see Table I). When dried mucilage concentration exceeded 0.2% w/v, the viscosity was very difficult to measure with the Ostwald viscometer. The dried mucilage had higher viscosity than the sodium carboxymethylcellulose.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here